Sorafenib Inhibits Doxorubicin-Induced PD-L1 Upregulation to Improve Immunosuppressive Microenvironment in Osteosarcoma
Authors:
Preprint
- 22 August 2022
- preprint
- Published by Springer Nature in Research Square
Abstract
Purpose: Although undergoing conventional chemotherapy significantly improves the prognosis of osteosarcoma, chemoresistance and failure of therapy is still a significant challenge. Furthermore, conventional chemotherapy, like doxorubicin, would upregulate the expression of Programmed death-ligand 1 (PD-L1) which caused an immunosuppressive microenvironment and unsatisfied treatment result in Osteosarcoma. Thus, it is urgent to explore a strategy to overcome this disadvantage.Methods: Human Osteosarcoma cell line MG63 and mouse Osteosarcoma cell line K7 were included in this study. Subcutaneous tumor model was used by injection K7 cells in BALB/C mice to test the effect of doxorubicin and sorafenib on tumor growth. PD-L1 expression was tested in vitro (flow cytometry, western blot and PCR) and in vivo (flow cytometry and immunohistochemistry). Proportion of immune cells (CD4, CD8, Tregs and cytotoxic T lymphocytes) in vivo was analyzed with flow cytometry.Results: Combination of sorafenib and doxorubicin inhibited tumor growth significantly in vivo. Doxorubicin increased PD-L1 expression in vitro and in vivo, while sorafenib inhibited doxorubicin-induced PD-L1 upregulation in vitro and in vivo. Proportion of interferon-γ-secreting CD8+ T lymphocytes in tumor tissue was increased significantly when combined sorafenib with doxorubicin, while proportion of CD4, CD8 and Tregs was not significantly changed. Extracellular Signal-Regulated Kinases (ERK) pathway could be one of the key mechanisms by which doxorubicin induced upregulation of PD-L1 in osteosarcoma cells.Conclusion: Combination of sorafenib and conventional chemotherapeutic reagents is a potent strategy to improve treatment effectiveness by modulating tumor micro environment in Osteosarcoma through increasing proportion of cytotoxic T lymphocytes.Keywords
All Related Versions
This publication has 38 references indexed in Scilit:
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- Lapatinib and doxorubicin enhance the Stat1‐dependent antitumor immune responseEuropean Journal of Immunology, 2013
- A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group studyAnnals of Oncology, 2011
- Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated with Autologous Tumor Cells Experiencing Immunogenic DeathCancer Research, 2010
- Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic moleculeBreast Cancer Research, 2010
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cellsJournal of Experimental Medicine, 2009
- Osteosarcoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-upAnnals of Oncology, 2009
- Cancer-related inflammationNature, 2008
- Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosisMolecular Immunology, 2008
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004